Overview

* Liquidia ( LQDA ) Q3 revenue of $51.7 mln beats analyst expectations

* Company achieves operating profitability in first full quarter of YUTREPIA sales

* Posts net loss; adjusted loss/share beats consensus

Outlook

* Liquidia ( LQDA ) plans to advance L606 into pivotal trials

* Company aims for sustained growth and profitability

* Liquidia ( LQDA ) sees YUTREPIA as a potential preferred treatment

Result Drivers

* YUTREPIA LAUNCH - Strong sales of YUTREPIA, with $51.7 mln in net product sales as launch momentum continues

* PRESCRIPTION GROWTH - Over 2,000 unique prescriptions and 1,500 patient starts contributed to sales momentum, as of Oct 30

* COST MANAGEMENT - Positive operating income and adjusted EBITDA reflect effective cost management alongside revenue growth

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $51.66 $18.82

REVENUE mln mln (8

Analysts

)

Q3 EPS Beat -$0.04 -$0.40

(9

Analysts

)

Q3 NET -$3.53

INCOME mln

Q3 $1.77

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Liquidia Corp ( LQDA ) is $37.00, about 34.2% above its October 31 closing price of $24.36

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)